Latest squamous cell carcinoma Stories

PARSIPPANY, New Jersey, March 14, 2012 /PRNewswire/ -- Ingenol mebutate was proven efficacious with a once-daily application for only 2 or 3 days Today, the New England Journal of Medicine (NEJM) published an analysis of pooled results from LEO Pharma's four Phase III clinical trials for ingenol mebutate gel, demonstrating that ingenol mebutate gel is safe and effective for the treatment of actinic keratoses (AKs) on the...

Absurd questions about revenue postpone important health legislation SCHAUMBURG, Ill., March 3, 2012 /PRNewswire-USNewswire/ -- The Idaho Dermatology Society (IDS) and the American Academy of Dermatology Association (AADA) are disappointed in the postponement of the vote by the Idaho House of Representatives on House Bill 486, which would ban the use of indoor tanning beds by minors under the age of 18. The vote was postponed due to the objections of the Idaho Freedom Foundation...

Over the past few decades, doctors have noted a surprising trend in cancer of the tonsils and base of the tongue. Though oral cancer previously appeared predominantly in elderly patients with a history of tobacco and alcohol use, it's increasing in younger patients: 30- to 50-year-old nonsmokers with the human papillomavirus (HPV). Fortunately, the newer form of cancer tends to be less aggressive, and the latest approach to treating the tumors can avoid the debilitating consequences of open...

New Jersey plastic surgeon, Dr. Paul M.Parker of the Parker Center for Plastic Surgery, encourages everyone to become more vigilant about skin cancer prevention even during the winter and spring. Paramus, NJ (PRWEB) February 21, 2012 With the increase in skin cancer due to sun exposure, New Jersey plastic surgeon, Dr. Paul M. Parker, MD, emphasizes how imperative skin cancer prevention is in all seasons, but especially now as the spring and summer are nearing . Skin cancer rates in the...

PARSIPPANY, N.J., Feb. 15, 2012 /PRNewswire/ -- The American Academy of Dermatology (AAD) and LEO Pharma want Americans to know that sunburns and premature aging aren't the only indications that their skin has been damaged by cumulative exposure to the sun. Research-based pharmaceutical company LEO Pharma has partnered with the AAD to launch Listen To Your Skin, a campaign aimed to raise awareness about the consequences and symptoms of cumulative sun damage including actinic...

MANHASSET, N.Y., Feb. 9, 2012 /PRNewswire-USNewswire/ -- Researchers led by a senior investigator at Hofstra-North Shore LIJ School of Medicine and The Feinstein Institute for Medical Research have released initial findings from a first-of-a-kind clinical trial in adaptive radiotherapy (ART) for head and neck cancer. The trial, sponsored by the National Cancer Institute, provides evidence that ART may benefit patients with less technical difficulty than previously believed. The...

Transplant patients who develop head and neck cancer are more likely to be non-smokers and non-drinkers, and less likely than their non-transplant counterparts to survive past one year of diagnosis, according to a new study from Henry Ford Hospital in Detroit. As part of a 20-year review, Henry Ford researchers found cancers of the throat, tonsils and mouth may be more aggressive in transplant recipients as the result of long-term immunosuppressive therapy required to prevent solid organ...

Nearly 12,000 people will die of head and neck cancer in the United States this year and worldwide cases will exceed half a million. A study published this week in the journal Carcinogenesis shows that in both cell lines and mouse models, grape seed extract (GSE) kills head and neck squamous cell carcinoma cells, while leaving healthy cells unharmed. “It’s a rather dramatic effect,” says Rajesh Agarwal, PhD, investigator at the University of Colorado Cancer Center and professor at...

COPENHAGEN, Denmark, January 26, 2012 /PRNewswire/ -- LEO Pharma today announced that Picato(R) (ingenol mebutate) gel (0.015%, 0.05%) has been approved by the US Food and Drug Administration (FDA) as a treatment for actinic keratoses (AK) on the face, scalp, trunk and extremities. Picato(R) gel is a once-daily, field-directed topical treatment for AK, a potential precursor to non-melanoma skin cancer caused by cumulative sun exposure. Treatment with Picato(R) gel is completed...

PARSIPPANY, N.J., Jan. 25, 2012 /PRNewswire/ -- LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato® (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). AK is a precancerous condition caused by cumulative sun exposure that has the potential to progress to squamous cell carcinoma (SCC), the second most common type of skin cancer.[1],[2] Picato® 0.015% gel is used once daily on the face and scalp for...